Regeneron Pharmaceuticals, Inc.
REGN
$771.33
$4.670.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -0.34% | 2.30% | 5.71% | 8.30% | 8.79% |
| Total Other Revenue | 36.43% | 17.39% | -2.24% | -10.61% | -3.94% |
| Total Revenue | 0.99% | 2.89% | 5.38% | 7.52% | 8.27% |
| Cost of Revenue | 11.95% | 13.18% | 13.94% | 13.07% | 13.55% |
| Gross Profit | -9.97% | -7.08% | -2.75% | 2.26% | 3.46% |
| SG&A Expenses | -8.61% | -6.30% | -1.85% | 6.59% | 12.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -1,900.00% | -- | -- | -- |
| Total Operating Expenses | 5.81% | 7.27% | 9.20% | 11.15% | 13.20% |
| Operating Income | -10.69% | -7.40% | -3.40% | -0.72% | -2.08% |
| Income Before Tax | 9.43% | 3.54% | 6.27% | 23.31% | 13.83% |
| Income Tax Expenses | 97.60% | 80.09% | 56.76% | 163.25% | 49.49% |
| Earnings from Continuing Operations | 2.09% | -1.64% | 3.17% | 16.63% | 11.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.09% | -1.64% | 3.17% | 16.63% | 11.61% |
| EBIT | -10.69% | -7.40% | -3.40% | -0.72% | -2.08% |
| EBITDA | -8.26% | -5.44% | -1.81% | 0.70% | -0.56% |
| EPS Basic | 5.49% | 0.50% | 3.58% | 15.65% | 10.35% |
| Normalized Basic EPS | 15.46% | -2.53% | 0.81% | 3.21% | 2.39% |
| EPS Diluted | 8.53% | 3.36% | 5.11% | 16.07% | 10.18% |
| Normalized Diluted EPS | 18.56% | 0.12% | 2.17% | 3.57% | 2.26% |
| Average Basic Shares Outstanding | -3.08% | -1.76% | -0.30% | 0.65% | 1.08% |
| Average Diluted Shares Outstanding | -5.65% | -4.28% | -1.73% | 0.09% | 1.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |